Episodes

Monday May 10, 2021
Monday May 10, 2021
Dr. Julie Burnier, Assistant Professor of Oncology and Pathology at McGill university, explains how liquid biopsies can provide critical information about ocular tumours including genetic signature, presence of circulating tumour cells, and other biomarkers of disease severity. Dr. Burnier discusses Uveal Melanoma, the most common intraocular tumour in adults, and how liquid biopsies are becoming front and center in the personalized management of this highly complex tumour.

Wednesday May 05, 2021
Microsoft’s Vision For an Accessible World Through Inclusive Design - Ricardo Wagner
Wednesday May 05, 2021
Wednesday May 05, 2021
Ricardo Wagner, Accessibility Lead for Microsoft Canada, shares inspirational stories of how inclusive design has influenced a global community of people with accessibility needs, including those with low vision. From the surgeon who could access a computer hands free to an artist with ALS who was able to continue creating using only her eyes, the broad-reaching, life changing impacts of Microsoft’s accessibility endeavours comes to light in this thought provoking interview.

Sunday May 02, 2021
Cataract Surgery: What To Expect - Dr. Debra-Meghan Sanft
Sunday May 02, 2021
Sunday May 02, 2021

Tuesday Apr 27, 2021
Be My Eyes: Over 4 Million Volunteers Helping the Blind See – Will Butler
Tuesday Apr 27, 2021
Tuesday Apr 27, 2021
Will Butler, VP at "Be My Eyes", talks about the popular smart phone app and its rapid global adoption among the blind and visually impaired as well as millions of volunteers. Will further shares stories of corporate partnerships established by Be My Eyes to help people with low vision navigate everything from performing computer updates to reading pregnancy test results.

Saturday Apr 24, 2021
TapTapSee: Leveraging Technology To Help the Low Vision Community - Brad Folkens
Saturday Apr 24, 2021
Saturday Apr 24, 2021
Brad Folkens, CEO of TapTapSee, explains how the application helps people who are blind or have low vision “see“ using their smart phones. Brad covers the origins of the company and its technology, common use cases, and how the technology can be improved in the coming years.

Tuesday Apr 20, 2021
Tuesday Apr 20, 2021
Randy Pierce, President of 2020 Vision Quest, shares his journey of vision loss and how he focused on his abilities rather than his disabilities to climb Mount Kilimanjaro and other notable peaks, train for and compete in the Boston marathon as a blind athlete, pen a book to inspire the masses, and become a motivational speaker giving keynote addresses across a range of industries and geographies.

Saturday Apr 17, 2021
Saturday Apr 17, 2021
Dr. Hemant Khanna discusses how a powerful gene editing tool called CRISPR has the potential to treat blinding diseases such as Leber Congenital Amaurosis and Retinitis Pigmentosa. Dr. Khanna further provides an overview of gene therapy for retinal disease, as well as a description of a novel approach to treating retinal degeneration using partial length proteins.

Tuesday Apr 13, 2021
Stories from a Guide Dog Mobility Instructor - Rob Cramer
Tuesday Apr 13, 2021
Tuesday Apr 13, 2021
Rob Cramer, Guide dog mobility instructor for CNIB, discusses his lifelong dream to work with guide dogs for people with low vision. Rob’s journey began at the age of 10 when his mother, diagnosed with Retinitis Pigmentosa, received her first guide dog. His path took him to Australia and eventually back to Canada, accumulating experience and powerful stories along the way that he shares with the audience in this interview.

Monday Apr 12, 2021
Monday Apr 12, 2021

Sunday Apr 11, 2021
Sunday Apr 11, 2021
Dr. Helen Dimaras discusses how empowering Retinoblastoma survivors and their families to have a greater role in the decision-making process of research projects has led to more inclusive, high-quality, and translatable results. The Canadian Retinoblastoma Research Advisory Board (CRRAB) is co-directed by patients, clinicians, allied healthcare providers, researchers, patient engagement experts, and policymakers.